-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40

Benzinga·11/06/2026 16:50:20
Listen to the news
Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.